A study on infectivity of asymptomatic SARS-CoV-2 carriers

https://pubmed.ncbi.nlm.nih.gov/32513410/

Ming Gao¹, Lihui Yang², Xuefu Chen³, Yiyu Deng⁴, Shifang Yang⁵, Hanyi Xu⁶, Zixing Chen⁷, Xinglin Gao⁸

Affiliations expand

PMID: 32513410

PMCID: <u>PMC7219423</u>

• DOI: <u>10.1016/j.rmed.2020.106026</u>

Free PMC article

Full-text linksCite

Abstract

Background: An ongoing outbreak of coronavirus disease 2019 (COVID-19) has spread around the world. It is debatable whether asymptomatic COVID-19 virus carriers are contagious. We report here a case of the asymptomatic patient and present clinical characteristics of 455 contacts, which aims to study the infectivity of asymptomatic carriers.

Material and methods: 455 contacts who were exposed to the asymptomatic COVID-19 virus carrier became the subjects of our research. They were divided into three groups: 35 patients, 196 family members and 224 hospital staffs. We extracted their epidemiological information, clinical records, auxiliary examination results and therapeutic schedules.

Results: The median contact time for patients was four days and that for family members was five days. Cardiovascular disease accounted for 25% among original diseases of patients. Apart from hospital staffs, both patients and family members were isolated medically. During the quarantine, seven patients plus one family member appeared new respiratory symptoms, where fever was the most common one. The blood counts in most contacts were within a normal range. All CT images showed no sign of COVID-19 infection. No severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections was detected in 455 contacts by nucleic acid test.

Conclusion: In summary, all the 455 contacts were excluded from SARS-CoV-2 infection and we conclude that the infectivity of some asymptomatic SARS-CoV-2 carriers might be weak.

Keywords: Asymptomatic carrier; Contacts; Infectivity; SARS-CoV-2.

Copyright © 2020 Elsevier Ltd. All rights reserved.

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures




Fig. 1

5

Chest CT images of Case...

Similar articles

• Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study.

Khan M, Khan H, Khan S, Nawaz M.J Med Microbiol. 2020 Aug;69(8):1114-1123. doi: 10.1099/jmm.0.001231.PMID: 32783802

 Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.

Barnabas RV, Brown E, Bershteyn A, Miller RS, Wener M, Celum C, Wald A, Chu H, Wesche D, Baeten JM; Hydroxychloroquine COVID-19 PEP Study Team.Trials. 2020 Jun 3;21(1):475. doi: 10.1186/s13063-020-04446-4.PMID: 32493478 Free PMC article.

• Asymptomatic SARS-CoV-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China.

Luo Y, Trevathan E, Qian Z, Li Y, Li J, Xiao W, Tu N, Zeng Z, Mo P, Xiong Y, Ye G.Emerg Infect Dis. 2020 Aug;26(8):1930-1933. doi: 10.3201/eid2608.201016. Epub 2020 Apr 24.PMID: 32330112 Free PMC article.

• The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China.

Yang Y, Peng F, Wang R, Yange M, Guan K, Jiang T, Xu G, Sun J, Chang C.J Autoimmun. 2020 May;109:102434. doi: 10.1016/j.jaut.2020.102434. Epub 2020 Mar 3.PMID: 32143990 Free PMC article. Review.

• The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.

Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y.Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.PMID: 32169119 Free PMC article. Review.